文献速递角膜与眼表疾病

供体糖尿病严重程度与角膜内皮移植术后1年结局

Diabetes Severity in Cornea Donors and 1-Year Outcomes in Recipients in the Diabetes Endothelial Keratoplasty Study: A Secondary Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2026-10-08

该研究为多中心随机临床试验的二次分析,纳入1097例接受低至中等风险DMEK的患者(1421只眼),评估供体糖尿病严重程度(严重度评分、HbA1c、AGEs/AOPs)与术后1年移植成功、内皮细胞丢失及形态学的关系。结论支持使用糖尿病供体角膜进行内皮角膜移植,无需额外术前检测或基于糖尿病状态的风险分层。

要点

  • 供体糖尿病严重程度评分、HbA1c、AGEs/AOPs与1年ECD及形态学无关。
  • 糖尿病供体角膜可用于内皮角膜移植,无需额外术前检测或风险分层。

核心结论

  • DMEK术后1年内皮细胞丢失和形态学不受供体糖尿病严重程度影响。
  • 无论糖尿病严重程度生物标志物数值如何,糖尿病与非糖尿病供体角膜的1年移植成功、ECL和细胞形态学相当。
  • 支持使用糖尿病供体角膜进行内皮角膜移植,无需额外术前检测或基于供体糖尿病状态的风险分层。

研究设计与样本

  • 多中心、双盲、随机临床试验的二次分析,在美国28个临床中心(46名外科医生)和13家眼库开展。
  • 纳入接受低至中等风险DMEK的1097例患者(1421只研究眼),中位年龄71岁(IQR 66-76),女性631例(57.5%)。
  • 1044只眼(95.2%)因Fuchs内皮性角膜营养不良接受DMEK。
  • AGE和AOP测量来自472名供体的子集(542只研究供眼角膜)。

主要发现

  • 供体HbA1c<6.5%的968只眼1年移植成功率为97.1%(95%CI 95.4%-98.4%)。
  • 供体HbA1c 6.5%-<7.5%组(n=194)1年移植成功率为97.4%(95%CI 93.9%-100.0%)。
  • 供体HbA1c 7.5%-<9.0%组(n=86)1年移植成功率为93.0%(95%CI 83.3%-98.8%)。
  • 供体HbA1c各组间平均ECD无显著差异;糖尿病严重程度评分、HbA1c、AGEs/AOPs与1年移植失败、ECD、细胞面积CV或HEX百分比均无关。

临床怎么用

  • 临床可使用糖尿病供体角膜进行内皮角膜移植手术。
  • 无需因供体糖尿病状态额外进行术前检测或风险分层。

局限性

  • 本研究为随机临床试验的二次分析。
  • AGE和AOP测量仅来自472名供体的子集(542只研究供眼角膜)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The effect of cornea donor diabetes severity on graft success, endothelial cell density (ECD), and morphometry after Descemet membrane endothelial keratoplasty (DMEK) is not known. OBJECTIVE: To determine whether graft success, corneal endothelial cell loss (ECL), and morphometric changes 1 year after DMEK are associated with cornea donor diabetes severity measured by severity score, donor's postmortem level of hemoglobin A1c (HbA1c), and postmortem advanced glycation end products (AGEs) or advanced oxidation end products (AOPs). DESIGN, SETTING, AND PARTICIPANTS: This was a secondary analysis of a multicenter, double-masked, randomized clinical trial at 28 clinical sites (46 surgeons) and 13 eye banks in the US among individuals undergoing low- to moderate-risk DMEK. AGE and AOP measurements were collected from a subset of donors. Data analysis was conducted from September 1, 2025, through April 30, 2026. INTERVENTION: DMEK performed with a cornea from a donor without or with diabetes, assigned using a minimization procedure (comparable to randomization) to achieve an approximate 2:1 distribution, respectively. MAIN OUTCOMES AND MEASURES: Graft success, ECL, coefficient of variation (CV) of cell area, and percentage of hexagonal cells (HEX) at 1 year from eye bank and postoperative specular central endothelial images. RESULTS: A total of 1097 individuals (1421 study eyes; median [IQR] age, 71 [66-76] years; 631 [57.5%] female) undergoing low- to moderate-risk DMEK (1044 [95.2%] for Fuchs endothelial corneal dystrophy) were included. AGE and AOP measurements were collected from a subset of 472 donors (542 study donor corneas). Among 968 eyes with a postmortem donor HbA1c level lower than 6.5%, the 1-year graft success rate was 97.1% (95% CI, 95.4%-98.4%), compared with 97.4% (95% CI, 93.9%-100.0%), 93.0% (95% CI, 83.3%-98.8%), and 95.8% (95% CI, 87.3%-100.0%) among eyes with a donor HbA1c level of 6.5% to less than 7.5% (n = 194), 7.5% to less than 9.0% (n = 86), and 9.0% or higher (n = 48), respectively (P = .72). There was no significant difference in mean ECD across donor HbA1c groups. Donor diabetes severity measured with severity score, donor HbA1c level, and AGE and AOP metrics was not associated with 1-year graft failure, ECD, CV in cell area, or HEX percentage. CONCLUSIONS AND RELEVANCE: This secondary analysis of a randomized clinical trial found that ECL and morphometry 1 year after DMEK were not affected by cornea donor diabetes severity. Comparable 1-year graft success, ECL, and cell morphometrics with tissue from donors with and without diabetes, regardless of the diabetes severity biomarker values observed, support the use of corneas from donors with diabetes for endothelial keratoplasty procedures without additional preoperative testing or risk stratification based on the diabetes status of the cornea donor. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05134480.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Greiner MA, Monnier VM, Arafah BM, et al. Diabetes Severity in Cornea Donors and 1-Year Outcomes in Recipients in the Diabetes Endothelial Keratoplasty Study: A Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2026. PMID: 42848388. doi:10.1001/jamaophthalmol.2026.4253

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。